A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Secukinumab (Primary) ; Ustekinumab
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms CLARITY
- Sponsors Novartis
- 09 Oct 2017 Planned End Date changed from 1 Aug 2018 to 22 Aug 2018.
- 09 Oct 2017 Planned primary completion date changed from 1 Aug 2018 to 19 Oct 2017.
- 09 Oct 2017 Status changed from recruiting to active, no longer recruiting.